Nu Skin Enterprises (NUS) Tops Q3 EPS by 19c; Issues Weak Q4 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nu Skin Enterprises (NUS) Can't Be Bought Until China Bottoms, Canaccord Genuity Says
November 5, 2014 10:38 AM ESTCanaccord Genuity analyst Scott Van Winkle weighed in on Nu Skin Enterprises (NYSE: NUS) following Q3 results and disappointing guidance, which has shares down 16% early. He said they are still waiting for a bottom and China and warned investors to stay... More
Nu Skin Enterprises (NUS) Buy Rating Maintained at Deutsche Bank
November 5, 2014 9:21 AM ESTDeutsche Bank maintained a Buy rating on Nu Skin Enterprises (NYSE: NUS) with a price target of $70. The stock declined sharply after it reported Q3 results.
Analyst Bill Schmitz Jr said, "While results were in-line on sales this quarter, weak 4Q guide and... More
Nu Skin Enterprises (NUS) Declares $0.345 Quarterly Dividend; 2.7% Yield
November 5, 2014 7:36 AM ESTNu Skin Enterprises (NYSE: NUS) declared a quarterly dividend of $0.345 per share, or $1.38 annualized.
The dividend will be payable on December 3, 2014, to stockholders of record on November 21, 2014, with an ex-dividend date of November 19, 2014.
The annual yield on the dividend is 2.7... More
Heavily-Shorted Herbalife (HLF) Surges Ahead of Q3 Results
November 3, 2014 10:04 AM ESTIn addition to settling a class action suit, speculators are bidding up (+6.5%) heavily-shorted Herbalife (NYSE:... More
